NeuroPace Yönetim

Yönetim kriter kontrolleri 2/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Joel Becker

İcra Kurulu Başkanı

US$1.8m

Toplam tazminat

CEO maaş yüzdesi	13.9%
CEO görev süresi	1.3yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	1.3yrs
Yönetim Kurulu ortalama görev süresi	3.6yrs

Son yönetim güncellemeleri

Recent updates

Why Investors Shouldn't Be Surprised By NeuroPace, Inc.'s (NASDAQ:NPCE) 58% Share Price Surge

Jan 22

NeuroPace, Inc. (NASDAQ:NPCE) Stock Rockets 39% But Many Are Still Ignoring The Company

Apr 17

NeuroPace announces U.S. distribution agreement with DIXI Medical

Aug 11

NeuroPace EPS misses by $32.45, beats on revenue; issues guidance

Jun 03

CEO Tazminat Analizi

Joel Becker'un ücretlendirmesi NeuroPace'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$30m
Mar 31 2024	n/a	n/a	-US$32m
Dec 31 2023	US$2m	US$248k	-US$33m

Tazminat ve Piyasa: Joel 'ın toplam tazminatı ($USD 1.79M ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 1.48M ).

Tazminat ve Kazançlar: Joel şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Joel Becker (56 yo)

1.3yrs

Görev süresi

US$1,785,337

Tazminat

Mr. Joel D. Becker serves as CEO & Director of at NeuroPace, Inc. since July 10, 2023 and serves as its President. He had been President of Cardiac Rhythm Management & Neuromodulation at Integer Holdings C...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Joel Becker	CEO, President & Director	1.3yrs	US$1.79m	Veri yok
Rebecca Kuhn	CFO, VP of Finance & Administration	24.5yrs	US$994.91k	0.17% $ 316.1k
Martha Morrell	Chief Medical Officer	20.3yrs	US$1.11m	0.46% $ 849.4k
Dylan St. John	Chief of Operations & Development	less than a year	Veri yok	Veri yok
Leah Akin	Acting General Counsel	less than a year	Veri yok	Veri yok
Kelley Nicholas	Vice President of Sales	1.5yrs	Veri yok	Veri yok
Amy Treadwell	Vice President of Human Resources	less than a year	Veri yok	Veri yok

1.3yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim: NPCE 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.3 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Joel Becker	CEO, President & Director	1.3yrs	US$1.79m	Veri yok
Joseph Lacob	Independent Director	27.8yrs	US$111.53k	1.22% $ 2.3m
Frank Fischer	Chairman of the Board	27yrs	US$152.85k	1.98% $ 3.7m
Uri Geiger	Independent Director	1.8yrs	US$218.80k	0.019% $ 35.7k
Renee Ryan	Independent Director	11.8yrs	US$124.03k	0.14% $ 262.3k
Nimesh Shah	Board Observer	no data	Veri yok	Veri yok
Lisa Andrade	Independent Director	3yrs	US$125.45k	0% $ 0
Rakhi Kumar	Independent Director	3.6yrs	US$126.53k	0.026% $ 47.6k

3.6yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: NPCE 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.6 yıldır).

NeuroPace Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

NeuroPace, Inc., Annual General Meeting, Jun 07, 2024

NeuroPace, Inc Announces Resignation of Irina Ridley as Chief Legal Officer and Corporate Secretary

Chief Medical Officer notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Neuropace, Inc. Announces Board Member Changes

NeuroPace, Inc., Annual General Meeting, Jun 13, 2022

Recent updates

NeuroPace, Inc. Announces FDA Submission of Three-Year Data from Post-Approval Study of the RNS System in Focal Epilepsy

NeuroPace, Inc. to Report Q3, 2024 Results on Nov 12, 2024

NeuroPace, Inc. Increases Revenue Guidance for 2024

NeuroPace, Inc. (NASDAQ:NPCE) Screens Well But There Might Be A Catch

NeuroPace, Inc. to Report Q2, 2024 Results on Aug 13, 2024

NeuroPace, Inc. Reaffirms Earnings Guidance for the Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Forecast to breakeven in 2026

NeuroPace, Inc., Annual General Meeting, Jun 07, 2024

NeuroPace, Inc. to Report Q1, 2024 Results on May 08, 2024

Is NeuroPace (NASDAQ:NPCE) Weighed On By Its Debt Load?

Consensus EPS estimates upgraded to US$1.17 loss

New minor risk - Profitability

NeuroPace, Inc. Provides Earnings Guidance for the Year 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Forecast to breakeven in 2026

NeuroPace: Picking Up The Pace

New minor risk - Share price stability

NeuroPace, Inc. to Report Q4, 2023 Results on Mar 05, 2024

NeuroPace, Inc Announces Resignation of Irina Ridley as Chief Legal Officer and Corporate Secretary

Why Investors Shouldn't Be Surprised By NeuroPace, Inc.'s (NASDAQ:NPCE) 58% Share Price Surge

NeuroPace, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter Ended December 31, 2023

Price target increased by 15% to US$10.50

Forecast to breakeven in 2026

Chief Medical Officer notifies of intention to sell stock

NeuroPace, Inc. Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal Study

Chief Medical Officer notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Consensus estimates of losses per share improve by 12%

NeuroPace, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Price target increased by 11% to US$7.80

New minor risk - Share price stability

Consensus revenue estimates increase by 14%

NeuroPace, Inc. Revises Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

NeuroPace, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Neuropace, Inc. Announces Board Member Changes

NeuroPace, Inc. Revises Earnings Guidance for the Year 2023

Price target increased by 7.7% to US$7.00

NeuroPace, Inc. (NASDAQ:NPCE) Stock Rockets 39% But Many Are Still Ignoring The Company

Full year 2022 earnings: EPS exceeds analyst expectations

Price target increased by 11% to US$6.50

NeuroPace, Inc. to Report Q4, 2022 Results on Mar 02, 2023

NeuroPace, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2022

Neuropace, Inc. Announces First Patient with Lennox-Gastaut Syndrome (Lgs) Was Treated in Its Feasibility Investigational Device Exemption (Ide) Study

Price target decreased to US$6.38

Price target decreased to US$6.38

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

NeuroPace, Inc. Revises Earnings Guidance for the Fiscal Year 2022

NeuroPace, Inc. to Report Q3, 2022 Results on Nov 08, 2022

NeuroPace Inc. Announces First Patient Implanted in NAUTILUS Pivotal Study for the Treatment of Idiopathic Generalized Epilepsy

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Neuropace, Inc. Provides Revenue Guidance for 2022

NeuroPace announces U.S. distribution agreement with DIXI Medical

NeuroPace, Inc. to Report Q2, 2022 Results on Aug 11, 2022

NeuroPace, Inc.(NasdaqGM:NPCE) dropped from Russell 2000 Growth Index

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

NeuroPace, Inc. Provides Revenue Guidance for the Year 2022

Neuropace Announces First Patient Treated in Pivotal Study Evaluating the Rns System in Adolescents

Price target decreased to US$11.60

NeuroPace, Inc., Annual General Meeting, Jun 13, 2022

NeuroPace, Inc. to Report Q1, 2022 Results on May 12, 2022

Consensus EPS estimates fall by 75%

Full year 2021 earnings: EPS exceeds analyst expectations

Full year 2021 earnings: EPS exceeds analyst expectations

NeuroPace, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Third quarter 2021 earnings released: US$0.34 loss per share

Less than half of directors are independent